The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2019 | Real world analysis of second-line osimertinib use for NSCLC in North West London
Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, of the Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, discusses his group’s real world analysis of the use of second-line osimertinib in EGFR-mutated non-small cell lung cancer (NSCLC) across North West London, which was presented at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland. Dr Newsom-Davis highlights the notable results in terms of EGFR mutation testing and the rates of treatment with osimertinib, and draws attention to how these data can impact economic evaluation; namely, NICE evaluation of osimertinib in the first-line setting.
